The 2022 Technology Showcase, organized by the National Cancer Institute Technology Transfer Center and the Frederick National Laboratory, is scheduled for the afternoon of September 7. – Free, half-day hybrid [….]
2022 Technology Showcase
Tech Opportunity Webinar: CytoSig, a Novel Software Platform Predictor of Cytokine Signaling Activity & Targeted Discovery
Published on :Join us for a TTC-hosted webinar and hear from NCI’s Dr. Peng Jiang about a new Cytokine Signaling Analyzer called “CytoSig.” This novel software-based platform provides both a database of [….]
Maryland Life Science Advisory Board Welcomes New Members
The Life Sciences Advisory Board added three new members, Ellington West of Sonavi Labs, Michael Weingarten of the National Cancer Institute, and GlaxoSmithKline’s KaShauna G. Rohlehr.
How to Partner with the Frederick National Lab and National Cancer Institute
Both the FNL and NCI look for partnerships that can aid their work while providing their partners’ resources and expertise. The lab’s partners often include big pharmaceutical and biotech companies that are more product-driven than NCI and FNL, which are more research-driven.
National Cancer Institute (NCI) Awards Baltimore’s Isoprene Pharmaceuticals, Inc. a Two-Year $2 Million Small Business Innovation Research (SBIR) Grant
University of Maryland, Baltimore (UMB) startup is part of University’s New Ventures Initiative, a highly selective program that works to accelerate commercialization and exit strategies
2021 Technology Showcase
Hear from inventors from the National Cancer Institute and the Frederick National Laboratory about technologies primed for commercialization and/or collaboration; great opportunity for biotech stakeholders and companies of all sizes, [….]
National Cancer Institute and Frederick National Laboratory Technology Showcase
OVERVIEW: *Free, half-day virtual event. *Hear from inventors from the National Cancer Institute and the Frederick National Laboratory about technologies primed for commercialization and/or collaboration; great opportunity for biotech stakeholders [….]
NCI Tech Opportunities Webinar: New HIV Vaccine to Treat and Prevent HIV
TTC is planning a technology opportunities webinar on July 13, 2021 from 11:00 am – noon, EST. Attendees will hear from the NCI’s Dr. Genoveffa Franchini about a new HIV [….]
NCI Technology Opportunities Webinar: “Complete Tumor Regression Seen in Colon Cancer and Leukemia Animal Models with a Novel High Efficacy Fluorinated Cytidine Therapeutic Compound”
The National Cancer Institute (NCI), Technology Transfer Center (TTC) will host a webinar to highlight a cancer therapeutic technology for collaborative development and/or licensing. The webinar presented by the technology inventor, Dr. Joel Morris, will highlight NCI’s novel, therapeutic fluorinated cytidine compound that shows high efficacy against colon cancer and leukemia. Studies indicated that the therapeutic compound can produce complete regression in xenograph mouse models with minimal effects on body weight. Registration is free.
Gaithersburg’s miRecule Inc. closes $5.7M to Create Breakthrough RNA Therapies for Cancer and Muscular Dystrophy
miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced today it has closed over $5.7M in seed funding. The funding round was led by Alexandria Venture Investments, along with Boutique Venture Partners, Pathway Bioventures, Alumni Ventures Group, and national angel investors, with additional funding coming from the Maryland Momentum Fund and the FSHD Society. This funding includes a non-dilutive $2M Phase II SBIR grant from the National Cancer Institute.